CN114146125B - Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity - Google Patents
Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity Download PDFInfo
- Publication number
- CN114146125B CN114146125B CN202111611894.4A CN202111611894A CN114146125B CN 114146125 B CN114146125 B CN 114146125B CN 202111611894 A CN202111611894 A CN 202111611894A CN 114146125 B CN114146125 B CN 114146125B
- Authority
- CN
- China
- Prior art keywords
- oral
- oral cavity
- helicobacter pylori
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000214 mouth Anatomy 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 206010019375 Helicobacter infections Diseases 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 19
- 229940041678 oral spray Drugs 0.000 claims abstract description 15
- 239000000668 oral spray Substances 0.000 claims abstract description 15
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 14
- 241000405414 Rehmannia Species 0.000 claims abstract description 13
- -1 compound chlorine quaternary ammonium salt Chemical class 0.000 claims abstract description 13
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 10
- 239000000460 chlorine Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- 210000004877 mucosa Anatomy 0.000 claims abstract description 6
- 241000244365 Ligusticum sinense Species 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract description 3
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- 229940034610 toothpaste Drugs 0.000 claims abstract description 3
- 239000000606 toothpaste Substances 0.000 claims abstract description 3
- 239000002324 mouth wash Substances 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 229940051866 mouthwash Drugs 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 abstract description 25
- 229940037467 helicobacter pylori Drugs 0.000 abstract description 25
- 238000002360 preparation method Methods 0.000 abstract description 17
- 208000025865 Ulcer Diseases 0.000 abstract description 10
- 231100000397 ulcer Toxicity 0.000 abstract description 10
- 230000002147 killing effect Effects 0.000 abstract description 8
- 206010006326 Breath odour Diseases 0.000 abstract description 7
- 208000032139 Halitosis Diseases 0.000 abstract description 7
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 15
- 230000035876 healing Effects 0.000 description 14
- 208000002399 aphthous stomatitis Diseases 0.000 description 10
- 208000007565 gingivitis Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 7
- 208000007117 Oral Ulcer Diseases 0.000 description 6
- 229960003022 amoxicillin Drugs 0.000 description 6
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 6
- 208000020670 canker sore Diseases 0.000 description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 6
- 229960000282 metronidazole Drugs 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 6
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010028034 Mouth ulceration Diseases 0.000 description 3
- 208000025157 Oral disease Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 244000241235 Citrullus lanatus Species 0.000 description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMHWNJGXUIJPKG-UHFFFAOYSA-N CC(=O)O[SiH](CC=C)OC(C)=O Chemical compound CC(=O)O[SiH](CC=C)OC(C)=O JMHWNJGXUIJPKG-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000735527 Eupatorium Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000002829 antibacterial sensitivity test Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- 210000004763 bicuspid Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000003464 cuspid Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000000334 effect on gingivitis Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 150000008145 iridoid glycosides Chemical class 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine preparations, and discloses a traditional Chinese medicine composition for inhibiting helicobacter pylori infection in an oral cavity, in particular to a traditional Chinese medicine preparation containing rehmannia root extract and used for killing helicobacter pylori infection in the oral cavity. Comprises the following active ingredients in percentage by mass: 0.005-0.18% of mucosa bactericidal factor compound chlorine quaternary ammonium salt; 0.1-0.5% of Ligusticum chuanxiong extract; 0.1-2.0% of rehmannia root extract; the balance of water and auxiliary materials. It can be made into oral spray or toothpaste additive. The components are synergistic, so that helicobacter pylori in the oral cavity can be effectively killed, the sterilization rate is 99.99%, and meanwhile, the oral mucosa is repaired, and the ecological balance of the oral cavity is maintained. Can be used for treating ulcer and halitosis.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, relates to an oral bacteriostatic agent, and in particular relates to a traditional Chinese medicine preparation containing rehmannia root extract and used for efficiently killing helicobacter pylori infected in the oral cavity.
Background
Helicobacter pylori (Helicobacter priori, H pylori) is a flagellum-like, helical, gram-staining, negative microaerophilic campylobacter, the stomach is the leading locus of H.priori, and gastrointestinal disease is mostly caused by helicobacter pylori infection. H.pyri has also been detected in recent years by researchers from oral plaque, saliva, mucosal tissue, vomit, and has been shown to be associated with the occurrence of a variety of oral diseases including recurrent oral ulceration, halitosis, periodontitis, caries, and the like. Patient oral h.pyri is consistent with intragastric h.pyri, which have the potential to spread each other. Pyrori has become one of the most highly pathogenic bacteria of human infection. At present, more medicines for treating helicobacter pylori in the stomach are available, western medicines are taken as main medicines, and antibacterial medicines are as follows: omeprazole, claritoxins, amoxicillin, metronidazole, but often cause gastric discomfort due to side effects. Although studies have demonstrated that current triple therapies are capable of scavenging H.pyrori in the stomach, they are not capable of scavenging H.pyrori in the oral cavity, which is associated with a particular "biofilm" of oral plaque. Thus, the oral cavity is another site of aggregation of H.pyri, which acts as one of many microorganisms in the oral cavity, affecting the micro-ecology of the oral cavity, either entirely or locally, and is prone to causing oral disease. In addition, oral h.pyri may be an important factor in intragastric h.pyri infection and recurrence, thus killing oral h.pyri may benefit both the oral and the stomach.
In view of the unsatisfactory oral H.pyri scavenging effect of oral antibiotics, and the increased resistance of H.pyri to antibiotics, western medicines for scavenging H.pyri in the oral cavity are currently unsatisfactory. The traditional Chinese medicine has the advantage of small side effect, and a plurality of traditional Chinese medicine extracts are developed in China at present and are used for treating helicobacter pylori in the oral cavity. For example, CN202110700916.8 discloses an oral cavity helicobacter pylori resistant traditional Chinese medicine extract, an oral cavity care product and a preparation method thereof, which are composed of 20-40 parts of kudzuvine root, 9-15 parts of baical skullcap root, 9-15 parts of coptis root, 5-15 parts of honeysuckle, 5-15 parts of Chinese gall, 3-10 parts of dandelion, 3-10 parts of wild chrysanthemum flower and 3-5 parts of raw liquorice. CN202011412711.1 discloses a Chinese medicinal composition for resisting helicobacter pylori infection, and a preparation method and application thereof, which is prepared from probiotics, lysozyme and Chinese medicaments: 15-30 parts of lysozyme, 10-20 parts of probiotics, 8-15 parts of clove leaves, 5-10 parts of wrinkled gianthyssop, 5-15 parts of eupatorium, 8-16 parts of evodia rutaecarpa and 7-15 parts of coptis chinensis. The defects of complex ingredients, high cost, easy recurrence, slow effect and the like generally exist. It is also necessary to develop an innovative Chinese medicine oral health preparation with high efficiency, simplicity and safety.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine preparation which has low cost, quick response and the function of promoting ulcer mucous membrane healing and can kill helicobacter pylori infected in the oral cavity.
In order to achieve the purpose of the invention, the technical scheme is as follows:
the traditional Chinese medicine preparation for inhibiting helicobacter pylori infection in the oral cavity comprises the following active ingredients in percentage by mass:
mucous membrane bactericidal factor compounded chlorine type quaternary ammonium salt compound 0.005-0.18%
0.1-0.5% of Ligusticum chuanxiong extract;
0.1-2.0% of rehmannia root extract;
the balance of water and auxiliary materials.
The preparation method of the rehmannia root extract comprises the following steps: pulverizing radix rehmanniae, adding 10 times of water, reflux extracting for 3-5 times each for 1.5 hr, mixing extractive solutions, decolorizing, and concentrating under reduced pressure to obtain radix rehmanniae distillate.
The main active components of the radix rehmanniae extract stock solution are iridoid glycosides, phenethyl alcohol glycosides, saccharides, amino acids, furan aldehyde derivatives, organic acids, microelements and the like. The preparation method is characterized by retaining the property of the original medicinal materials, being colorless and having the advantage of the original property of the genuine medicinal materials.
The mucosa bactericidal factor compound chlorine type quaternary ammonium salt compound is prepared from alkyl dimethyl benzyl ammonium chloride and dialkyl dimethyl ammonium chloride according to a proportion of 1:1 mass ratio. The structural general formula is as follows:
R 1 is C12-14 alkyl, R 2 ，R 2 Respectively C8-10 alkyl, which are the same or different.
The pharmacological action of the invention: the small dose of mucosa bactericidal factor compound chlorine type quaternary ammonium salt cooperates with the rehmannia root extract to play a role in sterilizing, resisting inflammation, resisting virus, preserving moisture and promoting healing, and the action mechanism is that the medicine is adsorbed to the surface of the thalli, permeates and diffuses through the cell wall, adheres to the cell membrane, penetrates the cell membrane and acts with the intracellular solubles to cause the death of the thalli. The ligusticum wallichii is aromatic and deodorized, and the rehmannia glutinosa are cooperated to relieve ulcer pain.
The main effects are as follows: killing helicobacter pylori in oral cavity, and balancing healthy ecology of oral cavity. Can be used for treating oral diseases caused by helicobacter pylori. The symptoms are dental ulcer, halitosis, dental caries, gingivitis and gingival bleeding.
The invention has the advantages that: 1. the components are synergistic, the helicobacter pylori in the oral cavity is effectively killed, the sterilization rate is 99.99%, and meanwhile, the oral mucosa is repaired, and the ecological balance of the oral cavity is maintained. 2. By matching with the drug treatment mode of the stomach helicobacter pylori disease, the oral helicobacter pylori is synchronously killed, so that the stomach H.pyri is more thoroughly and efficiently treated, and the recurrence rate is reduced; meanwhile, gingivitis caused by bacteria is effectively prevented and treated, and periodontal diseases developed by the gingivitis are effectively prevented and treated. 3. The rehmannia root extract is cooperated to effectively accelerate the healing of canker sore, can treat the canker sore, and has the effect of treating halitosis caused by helicobacter pylori infection. 4. The rehmannia root and the ligusticum chuanxiong hort extracts are added, so that the ulcer pain can be effectively relieved, and the canker sore caused by the stress and depression factors can be prevented. Has good development prospect. 5. The formula is simple, and three active substance preparations are prepared: medical purified water, plant bioactive components and medical grade bactericidal factors. The small dosage of the compound chlorine quaternary ammonium salt is not only a mucous membrane sterilization factor, but also a preservative. It can be made into oral spray, collutory or toothpaste additive. The detection by a third-party detection mechanism has no stimulation to mucous membrane, no teratogenicity and no toxicity to cells.
Detailed Description
For a better illustration of the invention, the following examples are given: wherein the Ligusticum wallichii extract is a commercial product purchased from Siam gold green bioengineering technology Co.
Example 1
The traditional Chinese medicine preparation for inhibiting helicobacter pylori infection in the oral cavity comprises the following active ingredients in percentage by mass:
mucous membrane bactericidal factor compounded chlorine type quaternary ammonium salt compound 0.005-0.18%
0.1-0.5% of Ligusticum chuanxiong extract;
0.1-2.0% of rehmannia root extract.
The balance of water and auxiliary materials.
The preparation method of the rehmannia root extract comprises the following steps: pulverizing radix rehmanniae, adding 10 times of water, reflux-extracting for 3 times each for 1.5 hr, mixing extractive solutions, decolorizing, and concentrating under reduced pressure to obtain radix rehmanniae distillate stock solution.
The mucosa bactericidal factor compound chlorine type quaternary ammonium salt compound is prepared from dodecyl dimethyl benzyl ammonium chloride and dioctyl dimethyl ammonium chloride according to the proportion of 1:1 mass ratio.
Suspension quantification experiment:
through 3 repeated tests, the Chinese medicinal preparation has the effect time of 1min, 2min and 3min at the test temperature of 20+/-1 ℃, and the killing logarithmic value of helicobacter pylori is shown in the table 1.
TABLE 1 killing effect of chlorine type quaternary ammonium salt and the preparation of the present invention on helicobacter pylori
Note that: negative control sterile growth
And (3) antibiotic sensitivity test, namely testing the sensitivity of the clinical oral H.pyri isolate to the medicine and the common antibiotic medicine by using a K-B paper sheet method, measuring the radius of a bacteriostasis ring of each antibiotic by using a vernier caliper, and judging sensitivity, moderate sensitivity and drug resistance by referring to a drug sensitivity test judgment standard formulated by Chinese medicine biological product identification. Results: the drug resistance of the invention is 2.0 percent (1/48), and the drug resistance of metronidazole, clarithromycin, amoxicillin, furazolidone, levofloxacin, gentamicin and erythromycin is respectively 83.3 percent (40/48), 33.3 percent (16/48), 14.6 percent (7/48), 6.3 percent (3/48), 29.2 percent (14/48), 52.1 percent (25/48) and 27.1 percent (13/48).
Application example 1
The traditional Chinese medicine preparation is used as an active ingredient and is prepared into an oral spray for killing helicobacter pylori in the oral cavity and inhibiting the growth of the helicobacter pylori in the oral cavity to treat gingivitis, and the experiment is combined with a hospital, and is as follows:
1. the method comprises checking oral cavity, dividing all subjects into gingivitis group and gingivitis-free group, collecting specimens, scraping the plaque on the gingival and subgingival of incisors, cuspids, premolars and molars on two sides of patients with sterile spatula, collecting 1ml saliva, and mixing thoroughly. 100 total mixed specimens were obtained. 78 H.pyri strains were isolated, cultured, identified and maintained, with a gingivitis patient H.pyri infection rate of 78%. (78/100).
2. The method comprises the following steps: patients with h.pyri gingivitis were randomized into A, B, C groups of 25 persons each, with metronidazole taken in group a; group B takes amoxicillin; the oral spray of the invention is used for group C, the oral spray of group A\B is used for three times a day, the oral spray is continuously used for 1 week, the oral spray of group C is used for three times a day after meals, and the clinical curative effect and the recurrence condition are observed.
3. As a result, the total clinical effective rate of the traditional Chinese medicine composition is 67.5% in the group A, 42.5% in the group B, 97.5% in the group C and very significant in the group 3 comparison (P < 0.01). The total effective rate of controlling the recurrence effect is 68.5% in group A, 45.2% in group B, 98.7% in group C, and the difference is significant (P < 0.01) in comparison with group 3. Confirmation: the oral spray is superior to metronidazole and amoxicillin in clinical curative effect and recurrence rate control of gingivitis infected by Hp, and has obvious curative effect on gingivitis infected by Hp.
Application example 2
The composition is used as an active ingredient to prepare an oral spray, kill helicobacter pylori in the oral cavity, inhibit the growth of the helicobacter pylori in the oral cavity, treat recurrent oral ulcer (RAu) infected with helicobacter pylori (Hp), and is combined with a hospital to be tested, wherein the test is as follows:
1. the method comprises oral examination, sample collection, scraping oral mucosa of a patient with a sterile spatula, collecting 1ml of saliva, and mixing thoroughly. 100 total mixed specimens were obtained. 69 H.pyri strains were isolated, cultured, identified and maintained, with a 79% H.pyri infection rate for patients with recurrent oral ulceration. (79/100).
2. The method comprises the following steps: patients with H.pyri recurrent oral ulceration were randomized into A, B, C groups of 25 persons each, group A taking metronidazole; group B takes amoxicillin; the oral spray of the invention is used for group C, the oral spray of group A\B is used for three times a day, the oral spray is continuously used for 1 week, the oral spray of group C is used for three times a day after meals, and the clinical curative effect and the recurrence condition are observed.
3. As a result, the total clinical effective rate of the traditional Chinese medicine composition is 60.5% in the group A, 40.5% in the group B, 96.8% in the group C and very significant in the difference (P < 0.01) in the group 3. The total effective rate of controlling the recurrence effect is 68.5% in group A, 40.2% in group B, 95.7% in group C, and the difference is significant (P < 0.01) in comparison with group 3. Confirmation: the oral spray is superior to metronidazole and amoxicillin in the RAu clinical curative effect of treating the infection Hp and the control of recurrence rate, and has obvious curative effect on RAU of the infection Hp.
The oral cavity specimen is collected again according to the method after the gingivitis patient is cured for a week, and the helicobacter pylori in the oral cavity is not detected as a result of the separation culture, which shows that the traditional Chinese medicine spray has a good helicobacter pylori killing effect.
Application example 3
The oral liquid is used as an active ingredient, and is prepared into a gargle, and the gargle can kill helicobacter pylori in the oral cavity, inhibit the growth of helicobacter pylori in the oral cavity, treat halitosis and canker sore simultaneously, and is combined with a hospital for experiments as follows:
1. the method comprises checking oral cavity, scraping oral mucosa of patient with sterile spatula, collecting 1ml of saliva, and mixing thoroughly. 100 total mixed specimens were obtained. 81 H.pyri strains were isolated, cultured, identified and maintained, with an H.pyri infection rate of 81% for patients with halitosis and canker sores. (81/100).
2. The method comprises the following steps: patients with H.pyrori-infected halitosis and canker sores were randomly divided into A, B, C groups of 25 persons each, each with the inventive mouthwash, control mouthwash and ordinary mouthwash, used 3 times a day, and observed for patient recovery.
3. The results were as follows:
note that: the mouth wash of the control group is prepared by adopting rehmannia to replace rehmannia and adopting the same formula and process as the invention.
Three groups of mouthwashes have antibacterial function in the use process, but common mouthwashes cannot help the healing of dental ulcer wound surfaces after cleaning oral cavities, and the contrast group mouthwashes have certain healing effect but have slow effect. From the test data, it can be found that the control mouthwash had a period of 6-10 days for the healing of canker sores without shortening the healing process of canker sores. When the oral antibacterial liquid is used for the fourth day, the healing rate of canker sore reaches more than 64%, and the healing process is obviously shortened.
Typical cases:
1. the male patients with age 42 have the repeated attack of oral cavity helicobacter pylori infection and the oral ulcer which is as long as 10 days, and the effects of using watermelon frost, borneol boron powder, chlorhexidine gargle, cydiodine tablet and the like are poor, so that the oral ulcer can only be properly relieved, the wound surface of the canker is large, the affected part is more, and the treatment period is long. The oral antibacterial liquid is sprayed into the oral cavity for daily oral care, 4-5 times a day, 10 ml/time, obvious alleviation and healing of 3 days, reduction of the quantity of affected parts, alleviation of pain feeling and shortening of the healing period of the wound surface of the dental ulcer to 4-5 days. After healing, the oral cavity was tested for the absence of helicobacter pylori.
2. The patient is female, the age is 53, the canker sore with unknown reasons repeatedly attacks, the disease course is up to 20 years, the ulcer surface is large, the children have the same symptoms, the family aggregation is presented, and the mouth wash is not used in habit. Watermelon frost, borneol and boron powder and the traditional Chinese medicine have poor conditioning effect. The oral antibacterial liquid is sprayed into the oral cavity for daily oral care, 5 times a day and 10 ml/time are carried out, the pain sensation of the oral ulcer on the first day is improved, the pain sensation is relieved on the second day, the oral ulcer surface becomes smaller on the third day, the partial ulcer surface heals on the fifth day, the eighth day is obviously improved, and the oral ulcer does not recur in three months. The healing effect of the dental ulcer is good. After healing, the oral cavity was tested for the absence of helicobacter pylori.
Claims (2)
1. The traditional Chinese medicine composition for inhibiting helicobacter pylori infection of the oral cavity is characterized by comprising the following active ingredients in percentage by mass:
0.005-0.18% of mucosa bactericidal factor compound chlorine quaternary ammonium salt;
0.1-0.5% of Ligusticum chuanxiong extract;
0.1-2.0% of rehmannia root extract;
the balance of water and auxiliary materials;
the mucosa bactericidal factor compound chlorine type quaternary ammonium salt compound is prepared from alkyl dimethyl benzyl ammonium chloride and dialkyl dimethyl ammonium chloride according to a proportion of 1:1 mass ratio, and the structural general formula is as follows:
R 1 is C12-14 alkyl, R 2 ，R 3 Respectively C8-10 alkyl, which are the same or different.
2. The Chinese medicinal composition for inhibiting helicobacter pylori infection in the oral cavity according to claim 1, which is formulated into an oral spray, mouthwash or toothpaste additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111611894.4A CN114146125B (en) | 2021-12-27 | 2021-12-27 | Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111611894.4A CN114146125B (en) | 2021-12-27 | 2021-12-27 | Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114146125A CN114146125A (en) | 2022-03-08 |
| CN114146125B true CN114146125B (en) | 2023-06-27 |
Family
ID=80452242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111611894.4A Active CN114146125B (en) | 2021-12-27 | 2021-12-27 | Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114146125B (en) |
-
2021
- 2021-12-27 CN CN202111611894.4A patent/CN114146125B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114146125A (en) | 2022-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108606939B (en) | Composition with oral health care function and application and preparation method thereof | |
| KR20010068273A (en) | Pharmaceutical compositions for preventing and treating allergic diseases and methods for preparation thereof | |
| CN108464963B (en) | Composition for oral cavity and application and preparation method thereof | |
| CN101147724A (en) | Medicine or sanitary product containing licorice flavone extraction for oral cavity | |
| US11806376B2 (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
| CN110946804A (en) | Mouthwash for preventing dental caries and oral ulcer and preparation method thereof | |
| CN104983752B (en) | A kind of Chinese medicine composition that treating mouth disease, oral-cavity article and preparation method | |
| CN1152697C (en) | Oral cavity bacteriostatic composition containing extract of Chinese herb lotus leaf | |
| WO2016010284A1 (en) | Toothpaste composition containing curcuma longa l., and preparation method therefor | |
| CN113332342A (en) | Traditional Chinese medicine extract for resisting oral helicobacter pylori, oral care product and preparation method thereof | |
| CN108478500B (en) | Composition for oral cavity and application thereof | |
| CN107320368B (en) | A kind of adult toothpaste and preparation method thereof grey containing Chinese mugwort | |
| CN114146125B (en) | Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity | |
| CN1554324A (en) | Chinese medicinal tooth-paste | |
| CN1234389C (en) | Chinese traditional medicine for treating oral disease and its preparing process | |
| CN1150927C (en) | Stomatopathy and throat disease treating health care medicine and its production process | |
| CN108066224A (en) | A kind of peace stomach ulcer toothpaste and preparation method thereof | |
| CN114601780A (en) | Anti-inflammatory and antibacterial traditional Chinese medicine compound mouthwash and preparation method thereof | |
| CN107213244B (en) | Chewable tablet beneficial to treatment of gingival bleeding and preparation method thereof | |
| Sushma et al. | Antibacterial Activity of Herbal Extracts against Oral Bacteria: An Invitro Study | |
| CN116251160B (en) | Pharmaceutical composition with antibacterial effect and preparation method and application thereof | |
| CN114796034A (en) | Toothpaste and preparation method thereof | |
| CN114404522B (en) | Chinese herbal medicine composition, gargle and preparation method | |
| CN112717030B (en) | Pharmaceutical composition for preventing and treating oral diseases and preparation method and application thereof | |
| CN113546137B (en) | A pharmaceutical composition for treating or preventing oral diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |